Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP traded up 6.8% on Thursday . The company traded as high as $8.80 and last traded at $8.58. 1,037,987 shares were traded during mid-day trading, a decline of 22% from the average session volume of 1,333,423 shares. The stock had previously closed at $8.03.
Analyst Ratings Changes
Separately, Wall Street Zen raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.
Get Our Latest Stock Report on AUPH
Aurinia Pharmaceuticals Stock Up 0.2%
The business's fifty day moving average is $8.07 and its two-hundred day moving average is $8.19. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of 30.88 and a beta of 1.15. The company has a quick ratio of 5.26, a current ratio of 5.93 and a debt-to-equity ratio of 0.16.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.08 by $0.08. Aurinia Pharmaceuticals had a net margin of 16.11% and a return on equity of 14.27%. The company had revenue of $62.47 million during the quarter, compared to analysts' expectations of $61.06 million. Equities analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Aurinia Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the stock. SBI Securities Co. Ltd. purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth approximately $25,000. GF Fund Management CO. LTD. acquired a new position in Aurinia Pharmaceuticals during the 4th quarter worth approximately $27,000. Tower Research Capital LLC TRC increased its position in shares of Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter worth $31,000. Finally, GAMMA Investing LLC lifted its position in shares of Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 1,744 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company's stock.
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
